Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-312 first-line tarlatamab plus durvalumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer
2024-520050-38-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Sep 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of tarlatamab in small cell lung cancer (SCLC) (2 arms), sponsored by Amgen. Primary endpoints: Overall survival and Progression-free survival by blinded independent central review. Planned start Sep 2025; status: authorised.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-520050-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520050-38-00.